These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
430 related articles for article (PubMed ID: 27221874)
1. Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study. Phiphatpatthamaamphan K; Vilaichone RK; Siramolpiwat S; Tangaroonsanti A; Chonprasertsuk S; Bhanthumkomol P; Pornthisarn B; Mahachai V Asian Pac J Cancer Prev; 2016; 17(4):1903-7. PubMed ID: 27221874 [TBL] [Abstract][Full Text] [Related]
2. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand. Prapitpaiboon H; Mahachai V; Vilaichone RK Asian Pac J Cancer Prev; 2015; 16(10):4353-6. PubMed ID: 26028098 [TBL] [Abstract][Full Text] [Related]
3. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy. Prasertpetmanee S; Mahachai V; Vilaichone RK Helicobacter; 2013 Aug; 18(4):270-3. PubMed ID: 23356886 [TBL] [Abstract][Full Text] [Related]
4. Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy. Furuta T; Shirai N; Xiao F; El-Omar EM; Rabkin CS; Sugimura H; Ishizaki T; Ohashi K Clin Gastroenterol Hepatol; 2004 Jan; 2(1):22-30. PubMed ID: 15017629 [TBL] [Abstract][Full Text] [Related]
5. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand. Srinarong C; Siramolpiwat S; Wongcha-um A; Mahachai V; Vilaichone RK Asian Pac J Cancer Prev; 2014; 15(22):9909-13. PubMed ID: 25520127 [TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of eradication regimen based on the bacterial susceptibility and CYP2C19 genotype in children with refractory Zhang YD; Dong QW; Zhang SH; Gu F; Zhang Y; Song HB; Zuo NY; Zhang SS; Ma L; Ding ZL Zhonghua Er Ke Za Zhi; 2020 Jan; 58(1):41-45. PubMed ID: 31905475 [No Abstract] [Full Text] [Related]
7. Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan. Sugimoto M; Sahara S; Ichikawa H; Kagami T; Ban H; Otsuka T; Andoh A; Furuta T Helicobacter; 2017 Feb; 22(1):. PubMed ID: 27213463 [TBL] [Abstract][Full Text] [Related]
9. Once-daily rabeprazole, levofloxacin, clarithromycin-MR, and bismuth for Helicobacter pylori eradication: A randomized study of 7 or 14 days (ONCE study). Auttajaroon J; Vilaichone RK; Chotivitayatarakorn P; Mahachai V Helicobacter; 2019 Oct; 24(5):e12615. PubMed ID: 31282081 [TBL] [Abstract][Full Text] [Related]
10. Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole. Ormeci A; Emrence Z; Baran B; Gokturk S; Soyer OM; Evirgen S; Akyuz F; Karaca C; Besisik F; Kaymakoglu S; Ustek D; Demir K Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):879-85. PubMed ID: 27010145 [TBL] [Abstract][Full Text] [Related]
11. Effect of CYP2C19 Gene Polymorphisms on Proton Pump Inhibitor, Amoxicillin, and Levofloxacin Triple Therapy for Eradication of Helicobacter Pylori. Lin YA; Wang H; Gu ZJ; Wang WJ; Zeng XY; Du YL; Ying SS; Zhang BH Med Sci Monit; 2017 Jun; 23():2701-2707. PubMed ID: 28577017 [TBL] [Abstract][Full Text] [Related]
12. Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole. Gawrońska-Szklarz B; Siuda A; Kurzawski M; Bielicki D; Marlicz W; Droździk M Eur J Clin Pharmacol; 2010 Jul; 66(7):681-7. PubMed ID: 20376628 [TBL] [Abstract][Full Text] [Related]
13. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin. Oh JH; Dong MS; Choi MG; Yoo HW; Lee SB; Park YI; Chung IS J Gastroenterol Hepatol; 2009 Feb; 24(2):294-8. PubMed ID: 18823430 [TBL] [Abstract][Full Text] [Related]
14. [Efficacy of H. pylori eradication depending on genetic polymorphism of CYP2C19, MDR1 and IL-1β]. Bakulina NV; Maev IV; Savilova IV; Bakulin IG; Il'chishina TA; Zagorodnikova KA; Murzina AA; Andreev DN Ter Arkh; 2019 Aug; 91(8):34-40. PubMed ID: 32598752 [TBL] [Abstract][Full Text] [Related]
15. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340 [TBL] [Abstract][Full Text] [Related]
16. Neither 10- nor 14-Day Sequential Treatment is better than Standard Triple Therapy for Helicobacter Pylori Eradication. Warrington E; López-Román O; Tirado Montijo R; Urbina R; Cruz-Correa M; Toro DH P R Health Sci J; 2016 Dec; 35(4):203-208. PubMed ID: 27898166 [TBL] [Abstract][Full Text] [Related]
17. Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial. Chen KY; Lin TJ; Lin CL; Lee HC; Wang CK; Wu DC World J Gastroenterol; 2015 Sep; 21(36):10435-42. PubMed ID: 26420970 [TBL] [Abstract][Full Text] [Related]
18. Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial. Chung JW; Jung YK; Kim YJ; Kwon KA; Kim JH; Lee JJ; Lee SM; Hahm KB; Lee SM; Jeong JY; Yun SC J Gastroenterol Hepatol; 2012 Nov; 27(11):1675-80. PubMed ID: 22849546 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of a triple therapy with rabeprazole, amoxicillin, and faropenem as second-line treatment after failure of initial Helicobacter pylori eradication therapy. Togawa J; Inamori M; Fujisawa N; Takahashi H; Yoneda M; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H Hepatogastroenterology; 2005; 52(62):645-8. PubMed ID: 15816496 [TBL] [Abstract][Full Text] [Related]
20. Microarray-Based Detection and Clinical Evaluation for Song Y; Dou F; Zhou Z; Yang N; Zhong J; Pan J; Liu Q; Zhang J; Wang S Biomed Res Int; 2018; 2018():2684836. PubMed ID: 30276203 [No Abstract] [Full Text] [Related] [Next] [New Search]